Sei Investments Co. Makes New Investment in Aclaris Therapeutics, Inc. $ACRS

Sei Investments Co. acquired a new position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 217,154 shares of the biotechnology company’s stock, valued at approximately $814,000. Sei Investments Co. owned approximately 0.16% of Aclaris Therapeutics at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of ACRS. XTX Topco Ltd purchased a new position in shares of Aclaris Therapeutics during the 2nd quarter valued at about $34,000. R Squared Ltd purchased a new stake in Aclaris Therapeutics in the fourth quarter worth approximately $37,000. The Manufacturers Life Insurance Company bought a new position in Aclaris Therapeutics during the second quarter valued at approximately $48,000. BNP Paribas Financial Markets grew its position in Aclaris Therapeutics by 59.0% during the third quarter. BNP Paribas Financial Markets now owns 26,667 shares of the biotechnology company’s stock valued at $51,000 after acquiring an additional 9,894 shares during the last quarter. Finally, CIBC Asset Management Inc bought a new position in Aclaris Therapeutics during the fourth quarter valued at approximately $52,000. 98.34% of the stock is currently owned by institutional investors.

Aclaris Therapeutics Trading Up 0.3%

Aclaris Therapeutics stock opened at $5.86 on Friday. The firm has a market cap of $819.35 million, a P/E ratio of -10.10 and a beta of 0.78. Aclaris Therapeutics, Inc. has a 1-year low of $1.67 and a 1-year high of $6.51. The firm has a 50-day moving average of $5.24 and a 200-day moving average of $4.38.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. Aclaris Therapeutics had a negative return on equity of 61.65% and a negative net margin of 921.50%.The business had revenue of $1.63 million during the quarter, compared to analyst estimates of $1.38 million. Research analysts forecast that Aclaris Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ACRS. Guggenheim started coverage on shares of Aclaris Therapeutics in a report on Tuesday, May 5th. They issued a “buy” rating and a $12.00 price objective for the company. Oppenheimer started coverage on shares of Aclaris Therapeutics in a report on Thursday, April 16th. They set an “outperform” rating and a $10.00 target price on the stock. Piper Sandler lifted their target price on shares of Aclaris Therapeutics from $7.00 to $11.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 5th. Wall Street Zen raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Wedbush boosted their price target on shares of Aclaris Therapeutics from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 29th. Three investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Aclaris Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $11.50.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical?stage biopharmaceutical company focused on discovering, developing and commercializing novel small?molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non?melanoma skin lesions. Lead programs include ATI?50002, a topical agent in late?stage development for molluscum contagiosum removal; ATI?50003 for common wart resolution; ATI?1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI?450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.